The Biochemical Bone Marker Market - Dawn or Dusk?
This article was originally published in Clinica
Executive Summary
Biochemical bone marker tests, especially those for bone resorption, are on the brink of being established as a routine tool in the management of osteoporosis. Until two years ago, the new market of resorption tests was one of the fastest growing sectors in immunodiagnostics. Nonetheless, the share prices of the two main players - Metra Biosystems and Ostex International - have reached an all-time low of below $1.00.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.